Search research articles
Contact Us
Filters
Showing results (51-60 of 83) with videos related to
Page
of 9
Sort By:
The Oncologist
|
February 12, 2020
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Donna Przepiorka, Lola Luo, Sriram Subramaniam, et al.
The Oncologist
|
August 25, 2017
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
Lee Pai-Scherf, Gideon M Blumenthal, Hongshan Li, et al.
The Oncologist
|
July 28, 2019
A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in <i>PTEN</i>
Takefumi Komiya, Gideon M Blumenthal, Roopa DeChowdhury, et al.
The Oncologist
|
December 16, 2017
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
Lauretta Odogwu, Luckson Mathieu, Kirsten B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2016
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
Erin Larkins, Gideon M Blumenthal, Huanyu Chen, et al.
Clinical Lung Cancer
|
March 24, 2020
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group
Patrick M Forde, Phil Bonomi, Alice Shaw, et al.
JCO Precision Oncology
|
September 11, 2020
Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology, US Food and Drug Administration Public Workshop-Workshop Proceedings
Hisani N Horne, Donna Roscoe, E David Litwack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2018
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer
Lynn J Howie, Nancy S Scher, Laleh Amiri-Kordestani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2021
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses
Kelly J Norsworthy, Xin Gao, Chia-Wen Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2019
FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Emily Y Jen, Xin Gao, Liang Li, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 83) with videos related to
Sort By:
Page
of 9
The Oncologist
|
February 12, 2020
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Donna Przepiorka, Lola Luo, Sriram Subramaniam, et al.
The Oncologist
|
August 25, 2017
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
Lee Pai-Scherf, Gideon M Blumenthal, Hongshan Li, et al.
The Oncologist
|
July 28, 2019
A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in <i>PTEN</i>
Takefumi Komiya, Gideon M Blumenthal, Roopa DeChowdhury, et al.
The Oncologist
|
December 16, 2017
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
Lauretta Odogwu, Luckson Mathieu, Kirsten B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2016
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
Erin Larkins, Gideon M Blumenthal, Huanyu Chen, et al.
Clinical Lung Cancer
|
March 24, 2020
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group
Patrick M Forde, Phil Bonomi, Alice Shaw, et al.
JCO Precision Oncology
|
September 11, 2020
Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology, US Food and Drug Administration Public Workshop-Workshop Proceedings
Hisani N Horne, Donna Roscoe, E David Litwack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2018
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer
Lynn J Howie, Nancy S Scher, Laleh Amiri-Kordestani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2021
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses
Kelly J Norsworthy, Xin Gao, Chia-Wen Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2019
FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Emily Y Jen, Xin Gao, Liang Li, et al.
Page
of 9